Posted on September 08, 2011
Two doses of the human papillomavirus (HPV) vaccine Cervarix were as effective as the current standard three-dose regimen after four years of follow-up, according to researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues. The results of the study, based on data from a community-based clinical trial of Cervarix in Costa Rica, appeared online Sept.9, 2011, in the Journal of the National Cancer Institute.
The National Cancer Institute (NCI) press release for the study
News article in NCI's bi-weekly newsletter the Cancer Bulletin
Feature article in the DCEG Linkage Newsletter
To request an interview with a DCEG investigator, contact the NCI Office of Media Relations: